Usefulness of dexmedetomidine in ultra-sono guided radiofrequency ablation of liver

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000838

Enrollment

Registered

2013-09-06

Start date

2013-09-09

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Dexmedetomidine group of patients was received with continuous infusion of 0.5 mcg/kg/hr dexmedetomidine after loading dose (1 mcg/kg during 15 minutes) infusion. Propofol group was received co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who American Society of Anesthesiologists physical status I-II patients more than 20 years scheduled to undergo elective percutaneous RFA of single tumor on liver under MAC

Exclusion criteria

Exclusion criteria: 1. negative Modified Allen's test 2. COPD 3. Cardiovascular disease 4. chronic kidney disease 5. Cerebrovascular disease

Design outcomes

Primary

Measure	Time frame
Opioid consumption	—

Secondary

Measure	Time frame
CO2 retention;Vital sign change;Iowa satisfaction with anesthesia scale	—

Countries

Korea, Republic of

Contacts

Public ContactKyoungwoon Joung

Asan Medical Center

Outcome results